Table 2 Neurologists’ experience with acute and prophylactic treatment
Total | Lithuania | Latvia | Estonia | p value | |
|---|---|---|---|---|---|
Triptan use in over 50% of migraine patients | 58.8% (N = 70) | 60.5% (N = 46) | 50.0% (N = 15) | 69.2% (N = 9) | 0.441 |
Oral migraine prophylaxis prescribed in over 50% of migraine patients | 26.9% (N = 32) | 30.3% (N = 23) | 20.0% (N = 6) | 23.1% (N = 3) | 0.532 |
Use of neuromodulation* | 22.7% (N = 27) | 18.4% (N = 14) | 33.3% (N = 10) | 23.1% (N = 3) | 0.256 |
Use of onabotulinumtoxin A for chronic migraine | 17.6% (N = 21) | 9.2% (N = 7) | 13.3% (N = 4) | 76.9% (N = 10) | < 0.001 |
Use of anti-CGRP monoclonal antibodies | 39.5% (N = 47) | 48.7% (N = 37) | 20.0% (N = 6) | 30.8% (N = 4) | 0.020 |